Adagene (ADAG) has released an update.
Adagene Inc. showcased promising clinical data at the SITC meeting, highlighting the safety and efficacy of its novel anti-CTLA-4 therapy, ADG126, in combination with pembrolizumab for treating metastatic colorectal cancer. The therapy demonstrated enhanced therapeutic potential and safety profiles, offering hope for improved cancer treatment strategies. These findings underscore ADG126’s potential as a leading therapy in the immunotherapy landscape.
For further insights into ADAG stock, check out TipRanks’ Stock Analysis page.
